Product #



Biochem/physiol Actions

Add to Cart

M121 (−)-MDO-NPA hydrochloride  
Q102 (−)-Quinpirole hydrochloride ≥98% (HPLC), solid Quinpirole is a dopamine agonist with high affinity for the D2 and D3 dopamine receptor subtypes. Specific [3H]quinpirole binding in rat brain was saturable, and dependent on temperature, membrane concentration, sodium concentration and guanine nucleotides. The putative D2 dopamine receptor agonist quinpirole (LY 171,555) is the most widely used D2 agonist in in vivo and in vitro studies. Quinpirole hydrochloride is an active enantiomer of (±)-quinpirole.Saturation analysis revealed high affinity binding characteristics (KD = 2.3 +/- 0.3 nM) which were confirmed by association-dissociation kinetics. The regional distribution of [3H]quinpirole binding sites roughly paralleled the distribution of [3H]spiperone binding sites, with greatest densities present in the striatum, nucleus accumbens and olfactory tubercles. A variety of drugs, most notably monoamine oxidase inhibitors (MAOls), inhibit the binding of [3H]quinpirole, but not [3H]spiperone or [3H](-)N-n-Propylnorapomorphine, in rat striatal membranes by a mechanism that does not appear to involve the enzymatic activity of MAO. Clinically antidepressant MAOIs exhibited selectivity between sites labeled by [3H]quinpirole and [3H]spiperone as did a number of structurally related propargylamines and N-acylethylenediamine derivatives and other drugs such as debrisoquin and phenylbiguanide. The MAOIs clorgyline and Ro 41-1049 were the most potent. MAOIs interact with a novel binding site that is labeled by [3H]quinpirole or that modulates [3H]quinpirole binding. This site may be associated with D2-like dopamine receptors.
S143 (±)-6-Chloro-PB hydrobromide ≥98% (HPLC), solid (+/-)-6-Chloro-PB HBr is a full D1 dopamine receptor agonist.
H8653 (±)-7-Hydroxy-2-(di-n-propylamino)tetralin hydrobromide (±)-7-Hydroxy-2-(di-n-propylamino)tetralin hydrobromide is a selective D3 dopamine receptor agonist (Kd <1nM); has much weaker affinity for other dopamine receptor subtypes.
P216 (±)-PD 128,907 hydrochloride solid, ≥98% (HPLC) Selective D3 dopamine receptor agonist.
D047 (±)-SKF-38393 hydrochloride crystalline, ≥98% (HPLC) (±)-SKF-38393 is a D1 dopamine receptor agonist. It is known to promote the production of glutamate in the hippocampus.
P183 (+)-PD 128,907 hydrochloride >97%, solid Selective D3 dopamine receptor agonist.
S101 (R)-(+)-SKF-38393 hydrochloride ≥98% (HPLC), solid D1 dopamine receptor agonist; active enantiomer of (±)-SKF-38393.
S178 (R)-SKF-82957 hydrobromide solid Selective D1 dopamine receptor agonist.
B2134 2-Bromo-α-ergocryptine methanesulfonate salt solid Bromocriptine is an ergot alkaloid and a dopamine D2 receptor agonist. It is prescribed for Parkinson′s disorder, hyperprolactinemia and galactorrhoea. It modulates β cells of the pancreas from insulin hypersecretion and improves the metabolic profile in type 2 diabetes patients with obesity. It also modulates glutamate release by glutamate transporter,GLT-1.
SML0608   A-412997 dihydrochloride ≥98% (HPLC) A-412997 is a selective D4 agonist with Ki values of 12 and 7.9 nM for the rat and human receptors, and no affinity for other dopamine receptors at concentrations up to 1 mM. A-412997 improves short term memory and cognitive properties in rodent models.
A255 A-77636 hydrochloride hydrate ≥98% (HPLC), solid Potent, orally active D1 dopamine receptor agonist.
A5111 ABT-724 trihydrochloride ≥98% (HPLC)  
SML0935   Aripiprazole ≥98% (HPLC) Aripiprazole is a second generation atypical antipsychotic and anti-depressant with partial agonist activity at dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors. Ki values are 0.34 nM, 0.8 nM, 1.7 nM, and 3.4 nM, respectively, for dopamine D2 and D3, serotonin 5-HT1A and 5-HT2A receptors. Aripiprazole is used in the treatment of schizophrenia.
Aripiprazole serves as a ‘dopaminergic stabilizer’. It is used as a potential therapeutic to treat schizophrenia patients. In addition, it is also preferably used to treat attention deficit hyperactivity disorder (ADHD) in patients with Tourette syndrome (TS).
B9308 BP897 >98% (HPLC), solid Partially selective D3 dopamine receptor agonist.
SML1670 Bifeprunox mesylate ≥98% (HPLC) Bifeprunox (DU-127,090) is an atypical antipsychotic. Bifeprunox is a dopamine D2 receptor (D2R) partial agonist that exhibits 5-HT1A agonist properties.
SML0080 CJB 090 dihydrochloride hydrate ≥98% (HPLC) CJB 090 is a Dopamine D3 receptor partial agonist. CJB 090 was found to attenuate the discriminative stimulus (DS) effects of cocaine while showing no cocaine-like effects when tested alone, and has also been shown to reduce methamphetamine self-administration.
PZ0101 CP-226269 ≥98% (HPLC) CP-226269 is a D4 dopamine receptor agonist with EC50 of 32 nM.
C0246 Cabergoline ≥98% (HPLC) Cabergoline, a lysergic acid amide derivative, is a potent dopamine D2 receptor agonist. It also acts on dopamine receptors in lactophilic hypothalamus cells to suppress prolactin production in the pituitary gland. It has been used for monotherapy of Parkinson′s disease in the early phase; combination therapy, together with levodopa and a decarboxylase inhibitor such as carbidopa, in progressive-phase Parkinson′s disease and adjunctive therapy of prolactin-producing pituitary gland tumors (microprolactinomas).
C130 Chloro-APB hydrobromide solid Full D1 dopamine receptor agonist.
SML0392 Dexpramipexole dihydrochloride ≥98% (HPLC) R-(+)-Pramipexole is a neuroprotective agent; weak non-ergoline dopamine agonist. R-(+)-Pramipexole has been found to have neuroprotective effects and is being investigated for treatment of ALS. It reduces mitochondrial reactive oxygen species (ROS) production, inhibits the activation of apoptotic pathways, and increase cell survival in response to a variety of neurotoxins and β-amyloid neurotoxicity. Compared to the S-(-) isomer, R-(+)-Pramipexole has much lower dopamine agonist activity.
H8502 Dopamine hydrochloride  
SML1172 FFN102 ≥98% (HPLC) FFN102 is a pH-responsive fluorescent false neurotransmitter that acts as a dopamine transporter substrate (DAT) and also a substrate for vesicular monoamine transporter 2 (VMAT2). FFN102 selectively labels dopamine cell bodies and dendrites in ventral midbrain and dopaminergic synaptic terminals in dorsal striatum. Its greater fluorescence emission in neutral than acidic environments allows the visualization of dopamine release at individual presynaptic terminals and in situ pH measurement of catecholamine secretory vesicles.
F9932 FFN511 trifluoroacetate salt hydrate ≥98% (HPLC) FFN511 is a fluorescent substrate for the synaptic vesicle monoamine transporters. FFN511 is used as an optical tracer of dopamine, a fluorescent false neurotransmitter (FFN) to visualize dopamine release from individual presynaptic terminals using time-lapse microscopsy fluorescence. The probe is sufficiently fluorescent so as to provide resolution of individual dopamine terminals at concentrations that do not interfere with normal catecholamine accumulation and transmission. FFN511 is compatible with GFPbased tags, the FM1-43 endocytic marker (Synapto Green), and other optical probes.
SML0198 Fenoldopam mesylate ≥98% (HPLC) Fenoldopam mesylate (FM) is considered as an effective therapeutic agent to prevent the onset of postoperative AKI (PO-AKI). In healthy cats, FM can stimulate diuresis and be well-tolerated. This benzazepine-derivative is regional specific and does not cause cerebral vasodilation.
Fenoldopam mesylate is a selective dopamine D1 receptor agonist used as an antihypertensive agent. It is an agonist for D1-like dopamine receptors and binds with moderate affinity to α2-adrenoceptors. It has no significant affinity for D2-like receptors, α1 and α-adrenoceptors, 5HT1 and 5HT2 receptors, or muscarinic receptors. Fenoldopam mesylate causes peripheral vasodilation by stimulating dopamine-1receptors and α2-adrenoceptors, increasing renal blood flow.
SML1331 MLS1547 ≥98% (HPLC) MLS1547 is a highly efficacious D2 dopamine receptor (D2R) G protein-biased agonist that does not recruit β-arrestin, and is an antagonist of dopamine-stimulated β-arrestin recruitment to the D2 receptor. MLS-1547 is the first D2 receptor agonist with close to full efficacy for G protein signaling (EC50 = 370 nM), but no ability to recruit β-arrestin.
S168 N-Allyl-(±)-SKF-38393 hydrobromide solid, ≥98% (HPLC) N-Allyl-(±)-SKF-38393 hydrobromide is a selective agonist of D1/D5 dopamine receptors. It mimics the physiological action of dopamine and enhances cognition, memory and learning. It decreases the age-related decline in long-term potentiation of mouse hippocampus. SKF-38393 increases the D1-mediated locomotion in rats.
SML1015   OS-3-106 ≥98% (HPLC) OS-3-106 is a potent and selective dopamine D3 receptor (D3R) partial agonist that blocked a D3R-mediated behavior in rats. OS-3-106 is effective in reducing cocaine self-administration.
PZ0177 OSU6162 hydrochloride ≥98% (HPLC) OSU6162 (PNU-96391) is a dopamine stabilizer, a drug that can stimulate or inhibit dopaminergic signaling depending on the dopaminergic tone. Dopaminergic stabilizers have been proposed to act as partial dopamine receptor agonists or as antagonists with both dopamine and behavioral stabilizing activity. Although affinity is not high (in vitro binding affinity for dopamine D2 receptor has a Ki of 447 nM), OSU6162 shows a high level of receptor occupancy.
O1141 Olanzapine ≥98% (HPLC) Olanzapine is a 5-HT2 serotonin and D1/D2 dopamine receptor antagonist.
P233 PD 168,077 maleate salt powder Selective D4 dopamine receptor agonist.
P9233 Piribedil maleate salt A direct dopamine agonist; may be selective for the D3 subtype; no significant affinity for D1 receptors.
A1237 Pramipexole dihydrochloride >98% (HPLC), powder Pramipexole elicits neuroprotective role and may help in treating depression. It also has a potential to modulate limb movement and may be effective in treating restless legs syndrome.
Pramipexole is a dopamine agonist active at D3 and D2 receptor subtypes. Pramipexole has been found to have neuroprotective effects independent of its dopamine receptor agonism. It reduces mitochondrial reactive oxygen species (ROS) production and inhibits the activation of apoptotic pathways.
Pramipexole is a therapeutic agent for Parkinson’s disease and restless leg syndrome. It also exhibits antidepressant responses in patients suffering from MDD (major depressive disorder) and bipolar depression.
B135 R(+)-6-Bromo-APB hydrobromide solid D1 Dopamine receptor agonist; potent enantiomer.
H168 R(+)-7-Hydroxy-DPAT hydrobromide >98%, solid Selective D3 dopamine receptor agonist; active enantiomer of (±)-7-hydroxy-DPAT.
S179 R(+)-SKF-81297 hydrobromide ≥98% (HPLC), solid SKF-81297 administration in spontaneously hypertensive rats (SHR) induces an increase in expression of proto-oncogene c-fos mRNA leading to biphasic effect on locomotion. It favors the turnover of phosphoinositide and adenylyl cyclase. SKF-81297 is involved in the stimulation of neurons, in particular the postsynaptic striatal neurons.
P102 R(+)-3-(3-Hydroxyphenyl)-N-propylpiperidine hydrochloride solid D2 dopamine receptor agonist. Also functions as σ1 receptor antagonist with essentially no affinity for the phencylidine site on the NMDA receptor.
A4393 R-(−)-Apomorphine hydrochloride hemihydrate calcined, ≥98.5% Nonselective dopamine agonist; causes nausea and emesis.
R2530 Ropinirole hydrochloride powder, ≥98% (HPLC) An agonist at the D2 and D3 dopamine receptor subtypes, binding with higher affinity to D3 than to D2 or D4. It has negligible effect on D1-receptors. It has medium in vitro affinity to opioid receptors. Ropinirole is said to have virtually no affinity to 5-HT1, 5-HT2, benzodiazepine, GABA, muscarinic, α1-, α2-, and β-adrenoreceptors. Used as antiparkinsonian drug.
Ropinirole hydrochloride is effectively used to treat early and late Parkinson′s disease.
R9281 Rotigotine hydrochloride ≥98% (HPLC) Rotigotine hydrochloride is a non-ergolinic D3/D2 and D1-dopamine agonist. It is appropriate for transdermal delivery through skin patches, that has the drug in a silicone-based adhesive matrix.
Rotigotine is a dopamine receptor agonist with preference for D3 receptors over D2 and D1. As such, it is an effective anti-Parkinsonian agent. Racemic rotigotine is about 50 times as potent as quinpirole, the gold standard D2 agonist.
S102 S-(−)-SKF-38393 hydrochloride solid D1 dopamine receptor agonist; less active enantiomer of (±)-SKF-38393.
SML1297   SB269652 ≥98% (HPLC) SB269652 is an allosteric modulator of D2 dopamine receptors. SB269652 binds to an allosteric site that is distinct from the orthosteric bound by typical D2 antagonists and is only revealed in D2 receptor dimers. SB269652 is bitopic, binding to an orthosteric site one one partner in the dimer and the allosteric site in the other. Engagement of this secondary pocket at the extracellular end of TM2 and TM7 is a new mechanism of modulating binding of a ligand to the orthosteric site of a second protomer by a G-protein coupled receptor.
S2941 SKF-75670 hydrobromide >98% (HPLC), solid Atypical D1 dopamine receptor agonist. Displays antagonist activity in vitro and agonist activity in vivo.
SKF-75670 is a selective dopamine D1 receptor agonist but with lower efficacy. It also acts as cocaine antagonist and alters the behavioral effects of cocaine in squirrel monkeys.
S2816 SKF-83959 hydrobromide ≥98% (HPLC), solid D1 dopamine receptor agonist. Displays antagonist activity in vitro and agonist activity in vivo.
SKF-83959 is an atypical agonist of D1 dopamine receptor and an allosteric modulator of σ-1 receptor on in brain and liver tissues. It has neuroprotective and anti-parkinsonian effects through selective activation of phosphoinositol-linked D1 receptor and promotes migration of cultures astrocytes by ERK1/2 activation. In in vitro studies SKF-83959 exhibits antagonist activity against dopamine D1 receptors coupled to adenylyl cyclase.
S3316 SKF-89145 hydrobromide >98% (HPLC), solid D1 dopamine receptor agonist.
SML0513 SKF83822 hydrobromide SKF83822 is a dopamine receptor agonist that only activates the D1 monomers and stimulates adenylate cyclase, but not PI hydrolysis.
SML0398 Salsolinol hydrobromide ≥96% (HPLC) Salsolinol is the condensation product of acetaldehyde and dopamine. Salsolinol is a potential neurotoxin suspected to contribute to alcohol abuse. It appears that salsolinol excites the ventral tegmental area (VTA) dopamine neurons indirectly by activating μ-opioid receptors (MORs), which inhibit GABA neurons in the VTA.
Salsolinol, a neurotoxin, can serve as a prolactin-releasing factor and an etiological factor in the tuberoinfundibular pathway and in Parkinson′s disease (PD), respectively. It can also act as a modulator of catecholaminergic neurotransmission in the nigrostriatal pathway. In central nervous system, salsolinol can change the role of dopaminergic neurons and dopamine metabolism.
SML1087 Sumanirole maleate ≥98% (HPLC) Sumanirole is a highly selective and potent dopamine D2 receptor agonist that decreased plasma prolactin levels and depressed dopamine neuron firing rates in the substantia nigra pars compacta. Sumanirole potently stimulates locomotor activity in in animal models of Parkinson’s disease.
T2879 Tyramine hydrochloride ≥98% Can enter catecholaminergic terminals and be released as a false transmitter.
Tyramine is a biogenic amine and a neuromodulator localized to the nervous system. Tyrosine decarboxylase catalysis the formation of tyramine from tyrosine. Tyramine is found to be associated with a number of psychiatric disorders. Tyramine ingestion depletes serotonin, epinephrine and norepinephrine reserves. This results in elevated biological events such as cardiovascular function, blood pressure, glucose production and overall metabolism. It also causes depression, migraine and insomnia. Tyramine is present is several food sources. The process of food fermentation and spoilage increases its tyramine content.
P0618 cis-8-Hydroxy-3-(n-propyl)-1,2,3a,4,5,9b-hexahydro-1H-benz[e]indole hydrobromide ≥98% (HPLC), solid D3 dopamine receptor agonist.